经济评估广泛用于预测新治疗方案的经济影响。针对慢性淋巴细胞白血病（CLL）领域的综合经济评估有必要补充现有针对特定治疗领域的分析。基于在Medline和EMBASE中的文献搜索，进行系统的文献综述，以总结与所有类型的CLL治疗相关的已发表健康经济模型。重点关注治疗比较、患者人群、建模方法和关键发现，进行有关研究的叙述综合。本文共包括29项研究，其中大多数是在2016至2018年间发表的，因为在这段时间内，CLL的大型临床试验数据变得可用。其中25项研究比较了不同的治疗方案，而其余四项研究则考虑了治疗策略的更复杂的患者路径。根据综述结果，马尔科夫建模是模拟成本效益的传统基础，其结构简单，包括三个卫生状态（无进展、进展、死亡）。然而，更近期的研究增加了进一步的复杂性，包括为不同治疗（如最佳支持性治疗或干细胞移植）添加额外的卫生状态，为无进展状态添加额外细分（如考虑治疗和非治疗），或为治疗反应状态添加额外细分（即部分反应和完全反应）。随着个性化医学越来越受到认可，我们预计未来的经济评估也将纳入新的解决方案，这些解决方案对于捕捉更多的遗传和分子标记以及个体化患者路径的更复杂的治疗选择和经济评估是必要的。 ©2023年作者。

Economic evaluations are widely used to predict the economic impact of new treatment alternatives. Comprehensive economic reviews in the field of chronic lymphocytic leukemia (CLL) are warranted to supplement the existing analyses focused on specific therapeutic areas.A systematic literature review was conducted based on literature searches in Medline and EMBASE to summarize the published health economics models related to all types of CLL therapies. Narrative synthesis of relevant studies was performed focusing on compared treatments, patient populations, modelling approaches and key findings.We included 29 studies, the majority of which were published between 2016 and 2018, when data from large clinical trials in CLL became available. Treatment regimens were compared in 25 cases, while the remaining four studies considered treatment strategies with more complex patient pathways. Based on the review results, Markov modelling with a simple structure of three health states (progression-free, progressed, death) can be considered as the traditional basis to simulate cost effectiveness. However, more recent studies added further complexity, including additional health states for different therapies (e.g. best supportive care or stem cell transplantation), for progression-free state (e.g. by differentiating between with or without treatment), or for response status (i.e. partial response and complete response).As personalized medicine is increasingly gaining recognition, we expect that future economic evaluations will also incorporate new solutions, which are necessary to capture a larger number of genetic and molecular markers and more complex patient pathways with individual patient-level allocation of treatment options and thus economic assessments.© 2023. The Author(s).